Ind-Swift Laboratories Ltd. released its earnings results on Nov 14, 2025. The company reported ₹1 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.

Is Ind-Swift Laboratories Ltd. overvalued?

According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ind-Swift Laboratories Ltd. pay dividends?

Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here

What is Ind-Swift Laboratories Ltd.’s EPS estimate?

Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ind-Swift Laboratories Ltd. have?

Ind-Swift Laboratories Ltd. has 81,611,560 shares outstanding.

What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?

Ind-Swift Laboratories Ltd. reported an EPS of ₹1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.07%.

Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:INDSWFTLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.